European Journal of Pediatrics

, Volume 166, Issue 1, pp 85–86 | Cite as

Persistent B-cell depletion after rituximab for thrombocytopenic purpura

  • Gianni BisognoEmail author
Short Report


Chronic immune thrombocytopenic purpura Rituximab Children B-cell immunodeficiency 


  1. 1.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125(2):232–239PubMedCrossRefGoogle Scholar
  2. 2.
    Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM (2002) Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100(3):1104–1105PubMedCrossRefGoogle Scholar
  3. 3.
    Mawhorter SD, Sierk A, Staugaitis SM, Avery RK, Sobecks R, Prayson RA, Procop GW, Yen-Lieberman B (2005) Fatal West Nile Virus infection after rituximab/fludarabine—induced remission for non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma 6(3):248–250PubMedCrossRefGoogle Scholar
  4. 4.
    Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G (2004) Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 163(6):305–307PubMedCrossRefGoogle Scholar
  5. 5.
    Taube T, Schmid H, Reinhard H, von Stackelberg A, Henze G, Overberg US (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90(2):281–283PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of PediatricsUniversity Hospital of PadovaPadovaItaly

Personalised recommendations